Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (51-60 of 177) with videos related to

Pageof 18
Sort By:
Frontiers in Oncology|May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myelomaLukas John, Kaya Miah, Axel Benner, et al.
Blood Cancer Journal|March 10, 2018
A systematic classification of death causes in multiple myelomaElias K Mai, Eva-Maria Haas, Stephan Lücke, et al.
Blood Cancer Discovery|February 4, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based CombinationsAnnamaria Gullà, Madhav V Dhodapkar, Hermann Einsele, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Cancer Immunology, Immunotherapy : CII|August 22, 2018
IL-10 inducible CD8<sup>+</sup> regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cellsJulian Plaumann, Melanie Engelhardt, Mohamed H S Awwad, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
International Journal of Cancer|September 9, 2014
T cell-based targeted immunotherapies for patients with multiple myelomaLei Wang, Nan Jin, Anita Schmitt, et al.
Genes, Chromosomes & Cancer|July 8, 2005
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsFriedrich W Cremer, Jelena Bila, Isabelle Buck, et al.
Pageof 18

Showing results (51-60 of 177) with videos related to

Sort By:
Pageof 18
Frontiers in Oncology|May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myelomaLukas John, Kaya Miah, Axel Benner, et al.
Blood Cancer Journal|March 10, 2018
A systematic classification of death causes in multiple myelomaElias K Mai, Eva-Maria Haas, Stephan Lücke, et al.
Blood Cancer Discovery|February 4, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based CombinationsAnnamaria Gullà, Madhav V Dhodapkar, Hermann Einsele, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Cancer Immunology, Immunotherapy : CII|August 22, 2018
IL-10 inducible CD8<sup>+</sup> regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cellsJulian Plaumann, Melanie Engelhardt, Mohamed H S Awwad, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
Cancer Discovery|April 25, 2013
Targeting the BRAF V600E mutation in multiple myelomaMindaugas Andrulis, Nicola Lehners, David Capper, et al.
Haematologica|March 12, 2010
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben, Anna Jauch, Uta Bertsch, et al.
International Journal of Cancer|September 9, 2014
T cell-based targeted immunotherapies for patients with multiple myelomaLei Wang, Nan Jin, Anita Schmitt, et al.
Genes, Chromosomes & Cancer|July 8, 2005
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsFriedrich W Cremer, Jelena Bila, Isabelle Buck, et al.
Pageof 18